Want to see NTHI full AI Analyst Report?
NTHI Stock Chart & Stats
$4.73
-$0.04(-1.02%)
At close: 4:00 PM EDT
$4.73
-$0.04(-1.02%)
Day’s Range― - ―
52-Week Range$2.96 - $12.99
Previous CloseN/A
Volume13.97K
Average Volume (3M)295.15K
Market Cap
$93.91M
Enterprise Value$110.08
Total Cash (Recent Filing)$1.97M
Total Debt (Recent Filing)$328.22K
Price to Earnings (P/E)―
Beta1.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,805,380
10 Day Avg. Volume261,719
30 Day Avg. Volume295,155
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside322.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Phase 2a Clinical EfficacyPositive Phase 2a results provide clinical validation for NEO100 in recurrent high-grade glioma, an area with limited treatment options. If confirmed in subsequent development, the observed disease control and survival could support regulatory progress, differentiation, and a durable commercial opportunity.
Proprietary CNS Oncology PlatformPatent protection through 2038 can help preserve exclusivity around NeOnc’s CNS drug candidates and delivery technologies. Combined with multiple NEO100 and NEO212 development programs, this platform may support sustained competitive differentiation if clinical and regulatory milestones are achieved.
Expanded Clinical And Regulatory FootprintInternational IND clearances expand the settings in which NeOnc can develop its candidates and run studies, complementing U.S. work. A broader trial footprint may improve development flexibility, increase access to patients, and create more opportunities to advance the pipeline toward registration.
Bears Say
Near-zero Revenue And Severe LossesThe company has not yet demonstrated commercial revenue scale, while operating costs substantially exceed reported sales. Extremely large losses relative to revenue indicate that commercialization remains distant or uncertain and that future progress depends heavily on successful clinical execution and additional funding.
Heavy And Worsening Cash BurnPersistent negative operating and free cash flow means NeOnc is consuming capital to fund its operations and clinical programs rather than generating internal financing. The deterioration from 2024 increases the likelihood of recurring fundraising and could constrain the pace or breadth of future development.
Negative Equity And Financing RiskDeeply negative equity weakens financial flexibility and signals that accumulated losses have overwhelmed the company’s capital base. Although the recent financing adds liquidity, issuing shares and warrants can dilute existing holders, while continued losses may require further capital and preserve balance-sheet pressure.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $2.96 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $93.91M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Undervalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 28,805,380 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (322.83% Upside)
$20.00 (322.83% Upside)
Blogger Sentiment
Bullish
NTHI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $668.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
NTHI Stock 12 Month Forecast
Average Price Target
$20.00
▲(322.83% Upside)
Technical Analysis
Ownership Overview
44.84% Insiders
1.12% Mutual Funds
6.27% Other Institutional Investors
45.89% Public Companies and
Individual Investors